ImmuPharma plc (LON:IMM – Get Free Report) dropped 11.6% during mid-day trading on Wednesday . The company traded as low as GBX 2.50 ($0.03) and last traded at GBX 2.57 ($0.03). Approximately 6,519,809 shares traded hands during trading, a decline of 43% from the average daily volume of 11,538,609 shares. The stock had previously closed at GBX 2.90 ($0.04).
ImmuPharma Stock Performance
The stock has a market cap of £10.27 million, a PE ratio of -4.18 and a beta of 1.53. The company’s 50-day moving average price is GBX 3.87 and its 200 day moving average price is GBX 2.49.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What is a buyback in stocks? A comprehensive guide for investors
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- When to Sell a Stock for Profit or Loss
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
